{"id":5463,"date":"2026-01-13T17:19:42","date_gmt":"2026-01-13T14:19:42","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5463"},"modified":"2026-01-13T17:24:59","modified_gmt":"2026-01-13T14:24:59","slug":"edgewise-therapeutics-shared-its-priorities-for-becker-and-duchenne-muscular-dystrophy-in-2026","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/edgewise-therapeutics-shared-its-priorities-for-becker-and-duchenne-muscular-dystrophy-in-2026\/","title":{"rendered":"Edgewise Therapeutics, 2026 Y\u0131l\u0131 i\u00e7in Becker ve Duchenne Kas Distrofisine Y\u00f6nelik \u00d6nceliklerini Payla\u015ft\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Edgewise Therapeutics, \u015firketin klinik programlar\u0131 (Becker Kas Distrofisi \/ Duchenne Kas Distrofisi) hakk\u0131nda g\u00fcncellemeler sa\u011flad\u0131 ve 2026 i\u00e7in \u00f6nemli kilometre ta\u015flar\u0131n\u0131 vurgulad\u0131.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2026 \u00d6ncelikleri \u2013 Sevasemten<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">GRAND CANYON k\u00fcresel kilit kohortunu tamamlayacak ve 2026&#039;n\u0131n d\u00f6rd\u00fcnc\u00fc \u00e7eyre\u011finde Becker&#039;deki bireylerle ilgili ilk sonu\u00e7lar\u0131 a\u00e7\u0131klayacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2027 y\u0131l\u0131n\u0131n ilk yar\u0131s\u0131nda Becker&#039;de sevasemten i\u00e7in ABD G\u0131da ve \u0130la\u00e7 \u0130daresi&#039;ne (FDA) Yeni \u0130la\u00e7 Ba\u015fvurusu (NDA) sunulmas\u0131 i\u00e7in haz\u0131rl\u0131klar yap\u0131lacak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (Duchenne) hastalar\u0131nda yap\u0131lacak Faz 3 klinik \u00e7al\u0131\u015fmas\u0131n\u0131n tasar\u0131m ve plan\u0131 2026 y\u0131l\u0131n\u0131n ikinci yar\u0131s\u0131nda tamamlanacakt\u0131r. &gt;&gt;&gt; <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/edgewise-therapeutics-reports-positive-results-on-sevasemten-program-for-becker-and-duchenne-muscular-dystrophies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sevasemten Nedir?<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Duchenne ve Becker i\u00e7in 2025 Ba\u015far\u0131lar\u0131<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Becker ile birlikte GRAND CANYON yeti\u015fkin kay\u0131t i\u015flemleri tamamland\u0131.<\/li>\n\n\n\n<li>Becker sendromlu yeti\u015fkinlerde yap\u0131lan MESA Faz 2 a\u00e7\u0131k etiketli uzatma \u00e7al\u0131\u015fmas\u0131ndan olumlu \u00f6n sonu\u00e7lar bildirildi.<\/li>\n\n\n\n<li>Duchenne kas distrofisi olan kat\u0131l\u0131mc\u0131larda LYNX Faz 2 plasebo kontroll\u00fc \u00e7al\u0131\u015fmas\u0131ndan elde edilen cesaret verici g\u00f6zlemler raporlanm\u0131\u015f olup, bu g\u00f6zlemler aras\u0131nda Ad\u0131m H\u0131z\u0131 95. Persentil (SV95C), Kuzey Y\u0131ld\u0131z\u0131 Ambulatuvar De\u011ferlendirmesi (NSAA) ve 4 basamakl\u0131 merdiven \u00e7\u0131kma testi gibi fonksiyonel \u00f6l\u00e7\u00fcmler yer almaktad\u0131r. Ayr\u0131ca Faz 3&#039;te de\u011ferlendirilecek 10 mg&#039;l\u0131k bir doz belirlenmi\u015ftir.<\/li>\n\n\n\n<li>Duchenne kas distrofisi olan ve daha \u00f6nce gen terapisi ile tedavi g\u00f6rm\u00fc\u015f kat\u0131l\u0131mc\u0131lar \u00fczerinde yap\u0131lan FOX Faz 2 plasebo kontroll\u00fc \u00e7al\u0131\u015fmas\u0131n\u0131n ilk sonu\u00e7lar\u0131 bildirildi; bu sonu\u00e7lar, 10 mg sevasemtenin fonksiyonel gerileme oran\u0131n\u0131 azaltma potansiyeline sahip oldu\u011funu da destekliyor.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Edgewise Therapeutics provided updates on the Company&#8217;s clinical programs (Becker Muscular Dystrophy \/ Duchenne Muscular Dystrophy) and highlighted major milestones for 2026. 2026 Priorities &#8211; Sevasemten Will complete the GRAND CANYON global pivotal cohort and will announce top-line results in individuals with Becker in the fourth quarter of 2026. Will prepare for submission of a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5464,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[67,66,151,152,150],"class_list":["post-5463","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-becker-muscular-dystrophy","tag-duchenne-muscular-dystrophy","tag-edgewise","tag-edgewise-therapeutics","tag-sevasemten"],"subtitle":"Edgewise Therapeutics, 2026 y\u0131l\u0131nda Becker ve Duchenne kas distrofisi klinik programlar\u0131na ili\u015fkin bilgileri ve 2025 y\u0131l\u0131ndaki \u00e7al\u0131\u015fmalar\u0131na dair detaylar\u0131 payla\u015ft\u0131.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5463"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5464"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}